Characteristics of the patients included in the study, at the time of ART initiation
| Patients, n | 42 |
| Age (years), median (IQR) | 38 (33–43) |
| Gender, % male | 78.6 |
| Heterosexual route of infection, % | 48.0 |
| Time from HIV diagnosis (weeks), median (range) | 52 (2–53) |
| Baseline CD4 (cells/mm3), median (range) | 351 (188–520) |
| Baseline CD8 (cells/mm3), median (range) | 1018 (726–1297) |
| Baseline viral load (log10 HIV RNA copies/mL), median (range) | 4.68 (4.30–5.01) |
| CDC stage C, % | 7.0 |
| Treatment, n | |
| 2 NRTIs + 1 NNRTI | 28 |
| 2 NRTIs + PI | 11 |
| other | 3a |
| Patients, n | 42 |
| Age (years), median (IQR) | 38 (33–43) |
| Gender, % male | 78.6 |
| Heterosexual route of infection, % | 48.0 |
| Time from HIV diagnosis (weeks), median (range) | 52 (2–53) |
| Baseline CD4 (cells/mm3), median (range) | 351 (188–520) |
| Baseline CD8 (cells/mm3), median (range) | 1018 (726–1297) |
| Baseline viral load (log10 HIV RNA copies/mL), median (range) | 4.68 (4.30–5.01) |
| CDC stage C, % | 7.0 |
| Treatment, n | |
| 2 NRTIs + 1 NNRTI | 28 |
| 2 NRTIs + PI | 11 |
| other | 3a |
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
aTwo with 3 NRTIs and one with 3 NRTIs + 1 NNRTI.
Characteristics of the patients included in the study, at the time of ART initiation
| Patients, n | 42 |
| Age (years), median (IQR) | 38 (33–43) |
| Gender, % male | 78.6 |
| Heterosexual route of infection, % | 48.0 |
| Time from HIV diagnosis (weeks), median (range) | 52 (2–53) |
| Baseline CD4 (cells/mm3), median (range) | 351 (188–520) |
| Baseline CD8 (cells/mm3), median (range) | 1018 (726–1297) |
| Baseline viral load (log10 HIV RNA copies/mL), median (range) | 4.68 (4.30–5.01) |
| CDC stage C, % | 7.0 |
| Treatment, n | |
| 2 NRTIs + 1 NNRTI | 28 |
| 2 NRTIs + PI | 11 |
| other | 3a |
| Patients, n | 42 |
| Age (years), median (IQR) | 38 (33–43) |
| Gender, % male | 78.6 |
| Heterosexual route of infection, % | 48.0 |
| Time from HIV diagnosis (weeks), median (range) | 52 (2–53) |
| Baseline CD4 (cells/mm3), median (range) | 351 (188–520) |
| Baseline CD8 (cells/mm3), median (range) | 1018 (726–1297) |
| Baseline viral load (log10 HIV RNA copies/mL), median (range) | 4.68 (4.30–5.01) |
| CDC stage C, % | 7.0 |
| Treatment, n | |
| 2 NRTIs + 1 NNRTI | 28 |
| 2 NRTIs + PI | 11 |
| other | 3a |
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
aTwo with 3 NRTIs and one with 3 NRTIs + 1 NNRTI.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
